JanOne

01/27/2023

In meetings hosted by Nasdaq MarketSite, the company reviewed its drug development programs that fight the opioid crisis through pharmaceuticals that reduce pain without causing addiction.

https://ir.janone.com/news-events/press-releases/detail/48/janone-charts-ambitious-strategic-course-for-non-addictive

07/22/2021

JanOne (Nasdaq: JAN) Selects CPC Clinical Research as Trial Manager for Phase 2b Study of JAN101 for Peripheral Artery Disease Patients

Read the full news release here: https://ir.janone.com/news-events/press-releases/detail/39/janone-selects-cpc-clinical-research-as-trial-manager-for

06/23/2021

JanOne (Nasdaq: JAN) Readies Clinical Supply of Lead Product Candidate JAN101 for Distribution to Phase 2b Trial Sites

Read the full news release here: https://ir.janone.com/news-events/press-releases/detail/38/janone-readies-clinical-supply-of-lead-product-candidate

06/22/2021

JanOne (Nasdaq: JAN) Selects Regulatory Partner for Phase 2b Trial as Investigational Plan is Prepared for FDA Filing

Read the full news release here: https://ir.janone.com/news-events/press-releases/detail/37/janone-selects-regulatory-partner-for-phase-2b-trial-as

06/15/2021

JanOne Appoints Internationally Renowned Expert on Addiction Nicholas Goeders, Ph.D. to Scientific Advisory Board

Read the full news release here: https://janone.com/janone-appoints-internationally-renowned-expert-on-addiction-nicholas-goeders-ph-d-to-scientific-advisory-board/

06/10/2021

JanOne (Nasdaq: JAN) Engages DC Consulting LLC for Government and Private Sector Initiatives

Read the full news release here: https://ir.janone.com/news-events/press-releases/detail/35/janone-engages-dc-consulting-llc-for-government-and-private

12/15/2020

Our CSO, Dr. Giordano, sat down with EricDye to discuss JanOne, the treatment of PAD, bringing to market drugs with non-addictive pain-relieving properties, and more.

Listen to the full interview here via eHealthRadio:

    Tony Giordano, PhD and Chief Scientific Officer of JanOne (NASDAQ: JAN), which is focused on developing treatments for diseases that cause severe pain joins eHealth Radio and and the Health News and Pain Management Channels. Listen to interview with...

09/24/2020

JanOne Successfully Begins Production of JAN101 cGMP Batch for Phase 2b Peripheral Artery Disease (PAD) Trial and Potential Covid-19 Study.

Read the full news release here: https://ir.janone.com/news-events/press-releases/detail/30/janone-successfully-begins-production-of-jan101-cgmp-batch

09/22/2020

JanOne (Nasdaq: JAN) Issues September 2020 Shareholder Letter Updating Investors on Recent Pharma Asset Potential for Peripheral Artery Disease.

Read the full news release here: https://ir.janone.com/news-events/press-releases/detail/29/janone-issues-september-2020-shareholder-letter-updating

09/21/2020

When treating PAD associated pain, 25% of patients are at risk for opioid prescriptions. If we treat PAD at the source, we remove the need for pain-relieving medications. Learn more here:

Our first drug candidate is to treat PAD and we have assembled an amazing team of experts in vascular science and pain.

09/16/2020

JanOne Announces Strategic Plan to Divest its Legacy Businesses.

Read the full news release here: https://ir.janone.com/news-events/press-releases/detail/28/janone-announces-strategic-plan-to-divest-its-legacy

09/11/2020

It's PAD Awareness Month. Click the link to learn more about Peripheral Artery Disease, the signs and symptoms and what you can do to help manage PAD via CardioSmart

Peripheral artery disease, or PAD, affects 8 million Americans—and many don't know they have it. But PAD is a very serious condition that has also been linked to heart attack and stroke if it's not treated.